Redbiotec

Redbiotec is a Swiss biotechnology company, founded as a spin-off from ETH Zurich, specializing in the development of novel vaccines and biologics. The company gained significant industry attention for its Redvax platform, which led to the acquisition of its Cytomegalovirus (CMV) vaccine program by Pfizer. Currently, Redbiotec focuses on its proprietary RedSieve platform to identify high-potency microbial metabolites for applications in oncology and immunotherapy. The company leverages its expertise in complex protein expression and microbiome analysis to develop next-generation therapeutic solutions. Redbiotec's business model combines internal drug discovery with strategic partnerships to advance its pipeline of anti-infectives and cancer treatments.